From the helm: Amplia (ASX:ATX), CEO & MD, Christopher Burns & Bell Potter Analyst, Thomas Wakim.

In this episode of From the helm, Grady is joined by Amplia Therapeutics (ASX:ATX) CEO & MD Dr Christopher Burns & Bell Potter Analyst Thomas Wakim to unpack the ongoing clinical trials for their prospective treatment drug for pancreatic cancer, and its substantial market opportunities in the US. Find Bell Direct here: Twitter: https://twitter.com/belldirect Facebook: https://www.facebook.com/BellDirectAu... LinkedIn: https://www.linkedin.com/company/bell... Instagram: https://www.instagram.com/bell.direct/ Threads: https://www.threads.net/@bell.direct